Cassava Sciences, Inc.
SAVA
$2.73
$0.1455.62%
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
--
Headlines
3/8/2025
-
MarketBeat
3/7/2025
-
Zacks Investment Research
3/5/2025
-
MarketBeat
3/4/2025
-
TipRanks Financial Blog
3/3/2025
-
Stock Options Channel
3/3/2025
-
MarketBeat
3/3/2025
-
MarketBeat
3/3/2025
-
GuruFocus
3/3/2025
-
The Fly
3/3/2025
-
Globe Newswire
2/27/2025
-
Seeking Alpha - Healthcare
2/27/2025
-
The Fly
2/27/2025
-
GuruFocus
2/27/2025
-
Globe Newswire
2/19/2025
-
Stock Options Channel
2/19/2025
-
MarketBeat
2/14/2025
-
ETF Channel
2/10/2025
-
GuruFocus
2/10/2025
-
PR Newswire
2/10/2025
-
GuruFocus
2/10/2025
-
GuruFocus
2/10/2025
-
PR Newswire
2/9/2025
-
PR Newswire
2/8/2025
-
GuruFocus
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Monday, March 3, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 5 and 9 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
512 501 2444
Address
6801 N. Capital of Texas Highway
Suite 300 - Building 1
Austin, TX 78731
Suite 300 - Building 1
Austin, TX 78731
Country
Year Founded
Business Description
Sector
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is...
more
